NuView Life Sciences

precision cancer diagnostics and therapeutics

improving patient outcomes and reducing healthcare costs.

NuView Life Sciences is working to improve the way cancer is diagnosed and treated in our modern healthcare system.

NuView Life Sciences is focused on creating precision cancer diagnostics and therapeutics to improve patient outcomes while reducing healthcare costs through the development and clinical application of its exclusive peptide analog technology, NV-VPAC1TM.

Led by a team of industry experts with decades of combined experience in healthcare and medical imaging technologies, NuView Life Sciences is poised to change how we look for and respond to cancer.

NuView Life Sciences has a strong mission – to change the way many types of cancer are diagnosed and treated using precision medicine technology. Diagnosing and treating cancer with a targeted, specific approach to the disease will help to increase positive patient outcomes while also driving down costs incurred by patients, healthcare providers, and third-party insurance payers.

Diagnostics

NuView Life Sciences’s leading technology, NV-VPAC1TM consists of a series of peptide analogs that target the vasoactive intestinal peptide receptor type 1 (VPAC1). The VPAC1 receptor becomes overexpressed in certain key malignancies including breast, prostate, colon, bladder, and endometrial cancer.

In Vivo Diagnostics

a Positron Emission Tomography (PET) imaging agent for the in vivo diagnosis of breast and prostate cancer

In Vitro Diagnostics

an in vitro diagnostic kit that may be used for detecting shed prostate and bladder cancer cells in voided urine

Therapeutic Applications

NuView Therapeutics intends to develop therapeutic applications of the NV-VPAC1TM technology by bringing…

From the Press

News

VPAC1-targeted PET/CT scan: improved molecular imaging for the diagnosis of prostate cancer using a novel cell surface antigen

Current approaches to prostate cancer screening and diagnosis are plagued with limitations in diagnostic accuracy. There is a compelling need for biomolecular imaging that will…
Press Releases

Binding Cell Receptors Key to New Prostate Cancer Diagnostic Test from NuView Life Sciences

A recent study validating urine diagnosis for cancer cell receptors in prostate cancer is eclipsing traditional methodology and warrants further steps toward FDA approval says…
Press Releases

Development of Precision Cancer Diagnostics Continues Amid Booming Tumor Profiling Market

The cancer (tumor) profiling market is expected to grow at a CAGR of 19.1% over the next four years. This growth directly reflects the public’s…